MindRank and CEO Zhangming Niu Recognized in Touzijia & Hurun Rankings Amid IPO Filing
MindRank
AI Drug Developer
Recently, several authoritative media outlets and research institutions have successively released industry rankings, recognizing outstanding companies and innovative figures driving the development of the pharmaceuticals and healthcare sector. "MindRank" has been selected."Investment Network·Top 40 Innovative Enterprises in the Life and Health Industry 2024""MindRank Founder and CEO Zhangming Niu Selected""2024 Hurun China Healthcare Young Entrepreneurs"
On November 29, 2024, Investment Network officially released the "2024 China Value Enterprise List"."MindRank" Selected as One of the "Top 40 Innovative Enterprises in the Life and Health Industry in 2024".
As an observer of the growth of innovative enterprises in the new economic era, the Investment Family Research Institute under the Investment Family Network continues to initiate the "Investment Family Network·2024 China Value Enterprise List" selection.Explore innovative companies that have profound implications for the future of China's economy.
After soliciting through online and offline channels, this selection received participation from more than 4,600 companies. The Investment Institute conducted a comprehensive evaluation based on five key dimensions—financing, technology, products, team, and influence—using the WFin database from Investment Network. After several months, they ultimately selected value-driven and innovative enterprises that met the criteria to form the "Investment Network · 2024 China Value Enterprise List."
Original link:
On December 5, 2024, Hurun Research Institute officially released the "Hurun China Healthcare Pioneering Young Entrepreneurs 2024" list."MindRank" Founder and CEO Zhangming Niu Selected for "2024 Hurun China Healthcare Young Entrepreneurs".
It is reported that this is the first time that Hurun Research Institute has released a ranking list focusing on young entrepreneurs in the medical industry. Candidate information was collected through recommendations from well-known investment institutions and industry experts, as well as information networks and databases across China. A comprehensive evaluation was conducted based on dimensions such as corporate position, enterprise value, and social influence, ultimately identifying the most outstanding individuals.Young entrepreneurs aged 45 and below who have made outstanding contributions to industry development.
The list also includes founders of companies such as Medlinker and Abogen Biosciences, covering sectors like medical services, gene testing/gene editing services, and innovative pharmaceuticals. Following his recognition in the Hurun China U40 Entrepreneur Award 2023, Zhangming Niu and "MindRank" have once again been acknowledged by the Hurun Research Institute for their outstanding achievements in promoting the AI-driven pharmaceutical industry with a mission of "Technology for Good."
Original link:
As the founder and CEO of "MindRank," Zhangming Niu has many years of R&D management experience in the AI pharmaceuticals industry and has served as a director/CTO of a German main-board listed AI healthcare company. With a long-term focus on AI-driven drug discovery research, Zhangming Niu has published dozens of peer-reviewed papers, including in several Nature and Cell series journals, as well as top artificial intelligence conferences, andLed "MindRank" with Molecule Pro™A series of technologies centered around and leading AI pharmaceutical platform applications.
Relying on a top-tier self-developed AI pharmaceutical platform and an innovative team, MindRank is continuously advancing a series of new drug pipelines with the potential to be first-in-class or best-in-class.MindRank's first self-developed GLP-1RA small molecule oral drug, MDR-001, is proceeding smoothly in Phase IIb clinical trials.，Multiple innovative drugs in the fields of oncology and metabolism have entered the IND-Enabling study stage. The team focuses on AI-powered innovative drug development to help bring better drugs to the public faster, enabling people to lead better lives.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby helping more lives regain health.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Enterprise List as one of "China's most socially impactful entrepreneurial companies."
Related Reading:
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Cooperation: bd@mindrank.ai
Other: info@mindrank.ai